AnBogen Therapeutics
Tracked across 13 events · 110 articles · First seen Jan 17, 2026 · Last active Aug 24, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: AnBogen Therapeutics announced two key research abstracts for its lead compound, Imofinostat (ABT-301), demonstrating its potential in enhancing immunotherapy for colorectal cancer and overcoming chemotherapy resistance in pancreatic cancer. The company is also advancing a Phase 1/2 clinical trial and plans for an Emerging Stock Market listing.
Apr 13, 2026 · 6 articles
Business
Impact: AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.
May 19, 2026 · 6 articles
Business
Impact: AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.
May 28, 2026 · 6 articles
Business
Impact: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
Business
Impact: Cyllene raised €33M Series C, rebranded, and advanced EG110A clinical development, positioning for Phase 2b/3 study in 2027.
Jul 07, 2026 · 6 articles
Business
Impact: Vistagen is the target of the stake acquisition. The investment and potential engagement could lead to strategic changes, boosting its stock price and providing validation for its pipeline.
Aug 04, 2026 · 6 articles
Business
AnBogen Therapeutics, Inc. (Nasdaq:PTGX) reported that on July 31, 2026, and August 17, 2026, it granted inducement awards to newly hired employees under its Amended and Restated Inducement Plan. The awards comprised options to purchase…
Impact: Protagonist granted inducement awards to new employees, reflecting ongoing talent acquisition. The company's pipeline includes ICOTYDE and rusfertide, with regulatory milestones ahead.
Aug 04, 2026 · 9 articles
Regulatory
AnBogen Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company, announced on August 20, 2026, that it received written responses from the U.S. United States — Food and Drug Administration (FDA) to its Type B pre-Investigational New…
Impact: AnBogen Therapeutics is the developer of PT00114 and the recipient of FDA's pre-IND feedback. This positive regulatory milestone supports its clinical development plans and may enhance its market position, though the company still faces substantial financial and clinical risks.
Aug 20, 2026 · 6 articles
Business
AnBogen Therapeutics Inc. (TPEx: 7784), a Taiwan-based clinical-stage precision oncology company, announced on August 24, 2026 that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of…
Impact: Anbogen is the primary company initiating the collaboration to advance its lead drug candidate ABT-301. The agreement could support clinical development and potentially increase the company's valuation.
Jul 20, 2026 · 6 articles
Tech
Impact: AnBogen Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced new data related to elacestrant and tagraxofusp at the 2026 ASCO Annual Meeting, and its partner Karyopharm Therapeutics presented data on selinexor.
May 25, 2026 · 33 articles
Business
Impact: Founding investor and development partner; CEO Ivar Hakonarson becomes Chairman of Synaptiq.
Jul 23, 2026 · 6 articles
90
United States — Food and Drug Administration provided pre-IND feedback AnBogen TherapeuticsFDA pre-IND feedback for PT00114
20
AnBogen Therapeutics granted inducement awardsProtagonist Therapeutics...
ERGEN INTELLIGENCE
Track AnBogen Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard